[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"digital-medicine\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:digital-medicine":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,54],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":34,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100639290","new-taipei-city-888-digital-medical-ai-platform-for-prevention-and-care-of-the-three-highs-and-cardio-renal-vascular-diseases-100639290",false,"NCT07588256","New Taipei City 888 Digital Medical AI Platform for Prevention and Care of the Three Highs and Cardio-Renal-Vascular Diseases","New Taipei City 888 Digital Medical AI Platform for the Prevention and Treatment of the Three Highs (Hypertension, Hyperglycemia, Hyperlipidemia) and Cardio-Renal-Vascular Diseases: Validation and Implementation Through Large-Scale Cluster Randomized Clinical Trials: T-888-DIGICARE-DREAM","DIGICARE-DREAM","Inclusion Criteria:\n\nI.T-888-DIGICARE：\n\nEligible participants must meet the definition of hypertension and at least one of the following chronic (non-hypertensive) conditions:\n\n1. Hypertension\n\n   * With or without treatment, and meeting one of the following:\n   * Office blood pressure: two consecutive measurements \\>130\u002F80 mmHg\n   * Home blood pressure: weekly average (morning\u002Fevening) \\>130\u002F80 mmHg, or more than half of the weekly measurements exceeding this threshold\n2. Hyperlipidemia\n\n   * With or without treatment, and\n   * LDL-C \\>100 mg\u002FdL (or \\>70 mg\u002FdL in patients with diabetes or established ASCVD)\n3. Diabetes Mellitus\n\n   * With or without treatment, and\n   * HbA1c \\>6.5%\n4. Chronic Kidney Disease (CKD)\n\n   * Estimated glomerular filtration rate (eGFR) \\\u003C60 mL\u002Fmin\u002F1.73 m², and\n   * Urine albumin-to-creatinine ratio (UACR) \\>30 mg\u002Fg\n5. Atherosclerotic Cardiovascular Disease (ASCVD):\n\n   * Including coronary artery disease, cerebrovascular disease, peripheral arterial disease, or aortic pathology\n\nII. DREAM-G:\n\n1. Hypertension\n\n   * With or without treatment, and meeting one of the following:\n   * Office blood pressure: two consecutive measurements \\>130\u002F80 mmHg\n   * Home blood pressure: weekly average (morning\u002Fevening) \\>130\u002F80 mmHg, or more than half of weekly measurements exceeding this threshold\n2. Hyperlipidemia\n\n   * With or without treatment, and\n   * LDL-C \\>100 mg\u002FdL (or \\>70 mg\u002FdL in patients with diabetes or established ASCVD)\n3. Diabetes Mellitus\n\n   * With or without treatment, and\n   * HbA1c \\>6.5%\n4. Chronic Kidney Disease (CKD)\n\n   * Estimated glomerular filtration rate (eGFR) \\\u003C60 mL\u002Fmin\u002F1.73 m², and\n   * Measurable urinary microalbumin-to-creatinine ratio\n5. Atherosclerotic Cardiovascular Disease (ASCVD):\n\n   • Including coronary artery disease, cerebrovascular disease, peripheral arterial disease, or aortic pathology\n\n   Participants must meet at least one of the above chronic disease conditions and:\n6. Untreated Hypertension:\n\n   * Morning home blood pressure (HBP) \\>130\u002F80 mmHg: weekly average (≥4 days) \\>130\u002F80 mmHg,\n   * Or more than half of morning HBP measurements (≥4 days per week) \\>130\u002F80 mmHg\n7. Treated Hypertension:\n\n   * Morning home blood pressure \\>130\u002F80 mmHg: weekly average (≥4 days) \\>130\u002F80 mmHg,\n   * Or more than half of morning HBP measurements (≥4 days per week) \\>130\u002F80 mmHg\n   * Average home blood pressure ≤130\u002F80 mmHg (used to determine treatment strategy)\n\nExclusion Criteria:\n\nI. T-888-DIGICARE\n\n1. Symptomatic heart failure (New York Heart Association functional class II-IV)\n2. End-stage renal disease requiring long-term dialysis\n3. Pregnant women or those planning pregnancy\n\nII. DREAM-G:\n\n1. Life expectancy \\\u003C1 year\n2. End-stage renal disease (ESRD) requiring regular renal replacement therapy, including dialysis, kidney transplantation, or palliative care\n3. Severe liver cirrhosis\n4. Malignancy under active treatment","ALL",{"count":19,"type":20},4162,"ESTIMATED","INTERVENTIONAL",[23],"NA","Non-communicable diseases (NCDs), or chronic diseases, are a major public health burden globally and in Taiwan, and control of the \"three highs\" (hypertension, dyslipidemia, and hyperglycemia) is a national priority. Nearly half of the 10 leading causes of death in Taiwan are directly or indirectly related to atherosclerotic cardiovascular disease (ASCVD), for which hypertension, dyslipidemia, and abnormal blood glucose are the major risk factors. National health insurance data indicate that over 70% of middle-aged and older adults have at least one of these chronic conditions. Early stages are often asymptomatic, and inadequate control may lead to complications of cardiovascular disease, stroke, renal vascular disease, and retinopathy, causing irreversible organ damage and death.\n\nFor blood pressure, large clinical trials such as SPRINT and STEP have shown that targeting systolic blood pressure below 130 mmHg significantly reduces ASCVD events. For LDL cholesterol, \"the lower, the better\" applies, with guideline-recommended LDL-C targets determined by baseline ASCVD risk, with levels below 55 mg\u002FdL for very high-risk patients. For diabetes, treatment goals generally include fasting plasma glucose below 130 mg\u002FdL and glycated hemoglobin (HbA1c) below 7%.\n\nAlthough antihypertensive therapy has been proven effective in preventing cardiovascular disease and chronic kidney disease attributable to hypertension, fewer than one-third of patients receiving antihypertensive medications achieve current guideline-recommended blood pressure targets. No randomized clinical trial to date has used home blood pressure as the primary therapeutic reference. Moreover, long-term evidence is lacking regarding the organ-protective effects of strategies targeting morning hypertension and of bedtime dosing regimens. Although the TIME study is currently the largest and longest-followed trial addressing dosing time, its bedtime-dosing arm was not specifically targeted to patients with morning hypertension. Therefore, we propose a clinical trial to investigate management strategies for morning hypertension. Aligned with the 2022 Taiwan Hypertension Guidelines, we will employ the \"722 protocol\" for home blood pressure monitoring and enroll patients with morning home blood pressure ≥130\u002F80 mmHg to compare selective nocturnal administration of antihypertensive agents versus exclusive morning dosing, assessing differences in morning home blood pressure control rates, end-organ damage, and atherosclerotic cardiovascular disease (ASCVD) events.\n\nThis project will implement two large-scale cluster-randomized clinical trials within the New Taipei City healthcare network. The first trial (T-888-DIGICARE) will evaluate whether a mobile digital health platform augmented with interactive digital modules can more effectively achieve the \"888\" targets for prevention and treatment of the Three Highs (Hypertension, Hyperglycemia, Hyperlipidemia). The second trial (DREAM-G) will use the same mobile health delivery model to investigate whether the timing of antihypertensive medication administration (nocturnal versus morning dosing) differentially affects patients with poor morning home blood pressure control. Beyond generating rigorous evidence through a novel clinical approach, this program is expected to have substantial global clinical impact and to showcase Taiwan's healthcare capabilities internationally. Operational challenges encountered and solutions developed during the trials will also provide critical feasibility data for the concurrent real-world implementation registry (T-888-DIGICARE-Registry). The registry will run in parallel with the cluster trials and will enroll individuals who decline trial participation at baseline as well as participants after trial completion, thereby serving as a continuity and real-world evidence platform.",[26,27,28,29,30,31,32,33],"Microalbuminuria","Microalbuminuria \u002FCreatinine Ratios ACR","Cardiovascular Disease Risk Factor","Cardiovascular Disease Prevention","Digital Medicine","Hypertension","Hyperglycaemia (Diabetic)","Hyperlipidemia",[35,36,37,38,39,40],"digital medicine","hypertension","home blood pressure monitoring","dyslipidemia","microalbuminuria","diabetes","RECRUITING","2026-05-11",{"date":44,"type":45},"2026-05-14","ACTUAL",{"date":47,"type":45},"2026-02-05",{"date":49,"type":20},"2029-02-05",{"name":51,"class":52},"New Taipei City Medical Association","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":21,"phases":64,"briefSummary":65,"conditions":66,"keywords":71,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":53},"100606123","cognitive-remediation-100606123","NCT07171450","Cognitive Remediation","Computerized Cognitive Remediation of Postviral Neurocognitive Dysfunction in Older Adults","Inclusion Criteria:\n\n* age ≥ 60 years old\n* prior history of COVID-19 that was confirmed with viral testing (e.g., positive laboratory test or positive at-home rapid test)\n* cognitive symptoms (e.g., memory or thinking concerns) following COVID- 19 infection that have lasted for at least 12 weeks and are still present\n* clinically meaningfully subjective cognitive concerns (i.e., T-score \\\u003C 40) on the PROMIS-Cognitive Function Scale\n* objective evidence of cognitive decline\\*, as defined by performance on standardized measures of executive functioning, memory, or processing speed from the NIH Toolbox Cognition Battery that is at least 1 standard deviation below estimated premorbid cognitive functioning \\[\\*at least one third of the sample, or 25 out of 75 subjects, will be required to meet this inclusion criterion\\]\n* fluent in English language\n* off psychiatric medication or on a stable dose for at least 8 weeks\n\nExclusion Criteria:\n\n* history of neurological disorder with potential to interfere with study participation or confound results (e.g., uncontrolled seizure disorder, moderate to severe traumatic brain injury or stroke with persistent neurological deficits)\n* history of dementia and\u002For dementia range performance on the Mini- Mental State Examination (i.e., score of less than or equal to 23)\n* prior diagnosis of Mild Cognitive Impairment (MCI) or Mild Neurocognitive Disorder unrelated to the participant's history of COVID-19\n* history of severe psychiatric illness that may interfere with study participation or confound results (e.g., bipolar disorder, schizophrenia, or other psychotic disorder)\n* history of significant neurodevelopmental condition that may interfere with study participation or confound results (e.g., intellectual disability, autism spectrum disorder, or specific learning disorder with impairment in reading)\n* alcohol or other substance use disorder within the past 2 years\n* significant sensory impairments (e.g., blindness) that would interfere with the ability to complete neuropsychological measures or engage in the tablet-based intervention\n* performance that is below expectation on a test of effort and validity","60 Years",{"count":63,"type":20},75,[23],"The goal of this clinical trial is to determine if a neuroscience-based computerized cognitive remediation (\"brain training\") program can treat neurocognitive dysfunction (i.e., memory or thinking difficulties) that emerges in some older adults following a viral infection. The main questions it aims to answer are:\n\n* Does computerized cognitive remediation improve cognitive performance and day-to-day functioning in older adults with postviral neurocognitive dysfunction?\n* Will treatment effects be maintained over time, leading to better long term cognitive outcomes?\n* Does the treatment lead to reductions in blood-based markers of inflammation as a potential mechanism of cognitive symptom improvement?\n* Can the treatment be optimized and refined based on feedback from participants to improve user (patient) experience? Researchers will compare the computerized cognitive remediation program to an active computer-based control condition (alternative computer activities) to see if the computerized cognitive remediation program works to treat postviral neurocognitive dysfunction.\n\nParticipation takes approximately 43-48 hours over 7 months, with most activities (40-46 hours) completed within the first 7-8 weeks, including:\n\n* Initial intake visit: Eligibility confirmation (\\~2-3 hours)\n* Computer activities: About 5 hours per week for \\~6 weeks (total \\~30 hours) completed on a computer tablet provided by the study and loaned to participants for use during the treatment phase\n* Weekly remote check-in meetings: \\~30 minutes each during treatment\n* Blood draws: Two sessions (before and after treatment), \\~20-30 minutes each\n* Three research visits: Pre-treatment, post-treatment, and 6-month follow-up (\\~2-3 hours each, including assessments of cognitive, emotional, and daily functioning)",[67,68,58,69,70,30],"Aging","Inflammation","Cognitive Dysfunction","Postviral Syndrome",[67,68,58,72,70,35],"Cognitive dysfunction","2026-02-20",{"date":75,"type":45},"2026-02-24",{"date":77,"type":45},"2026-01-21",{"date":79,"type":20},"2030-02-28",{"name":81,"class":52},"Cutter Lindbergh"]